Randomized controlled trials demonstrate attainable and sustainable remission targets with anifrolumab in systemic lupus erythematosus, indicating potential long-term damage reduction.
LLDAS and DORIS remission, which are associated with favourable outcomes such as reduced damage and mortality in patients with SLE, are attainable and sustainable treatment targets with long-term anifrolumab treatment.
No takes yet. Share an insight, caveat, or question.
Morand et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: